Upadacitinib-Induced Remission in Multicentric Reticulohistiocytosis: Expanding the Therapeutic Role of JAK Inhibition
International Journal of Molecular Sciences · 23.03.2026 · 27 (6) · 2898
DOI: 10.3390/ijms27062898 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.03.2026. Verfasst von Cristina Pamfil und 6 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Department, Emergency County Clinical Hospital Cluj, 400347 Cluj-Napoca, Romania. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Heterocyclic Compounds, 3-Ring, Histiocytosis, Non-Langerhans-Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Romania's National Recovery and Resilience Plan through the Romanian Ministry of Investment and European Projects, Romania’s National Recovery and Resilience Plan.
Abstract (Originalsprache)
Multicentric reticulohistiocytosis (MRH) is a rare systemic histiocytic disorder of uncertain etiology characterized by papulonodular cutaneous lesions and potentially destructive polyarthritis, with variable multisystem involvement. Owing to its low prevalence, evidence for optimal management remains limited, and treatment responses are heterogeneous. Emerging reports suggest that Janus kinase (JAK) inhibition may provide benefit in refractory disease. We report a 60-year-old woman with MRH presenting with papulonodular skin lesions, symmetric polyarthritis, constitutional symptoms, and interstitial lung disease (nonspecific interstitial pneumonia pattern) in the context of co-existing primary biliary cholangitis and no evidence of malignancy. Prior therapies (glucocorticoids, methotrexate, leflunomide) achieved suboptimal control. Upadacitinib, a selective JAK1 inhibitor, induced rapid and complete remission of cutaneous and articular disease with improvement of pulmonary involvement. Secondary weight gain and incident diabetes were managed with tirzepatide. This case adds to the limited literature supporting JAK inhibition as a targeted option for refractory MRH, including multisystem disease with pulmonary involvement. Systematic evaluation of efficacy, durability, and safety is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rheumatology Department, Emergency County Clinical Hospital Cluj, 400347 Cluj-Napoca, Romania.
- Department of Dermatology, "Iuliu Hațieganu" University of Medicine and Pharmacy Cluj-Napoca, 400012 Cluj-Napoca, Romania.
- Regional Institute of Gastroenterology and Hepatology "Octavian Fodor", 3rd Medical Clinic, 400394 Cluj-Napoca, Romania.
- Department of Dermatology, Emergency County Clinical Hospital Cluj, 400347 Cluj-Napoca, Romania.
- Medical and Surgical Sciences Department, University of Cordoba, 14071 Córdoba, Spain.
ORCID-Profile: Laura Damian
Förderung
- Romania's National Recovery and Resilience Plan through the Romanian Ministry of Investment and European Projects
- Romania’s National Recovery and Resilience Plan
Zitieren
APA
Pamfil, C., Taki, M. A., Candrea, E., Damian, L., Mihon, M. I., Moldovan, D. M. M., & Rednic, S. (2026). Upadacitinib-Induced Remission in Multicentric Reticulohistiocytosis: Expanding the Therapeutic Role of JAK Inhibition. International Journal of Molecular Sciences, 27(6), 2898. https://doi.org/10.3390/ijms27062898
Vancouver
Pamfil C, Taki MA, Candrea E, Damian L, Mihon MI, Moldovan DMM, et al. Upadacitinib-Induced Remission in Multicentric Reticulohistiocytosis: Expanding the Therapeutic Role of JAK Inhibition. International Journal of Molecular Sciences. 2026;27(6):2898. doi:10.3390/ijms27062898
BibTeX
@article{Pamfil2026,
author = {Pamfil, Cristina and Taki, Mohamed Amin and Candrea, Elisabeta and Damian, Laura and Mihon, Maia Ioana and Moldovan, Diana Maria Margareta and Rednic, Simona},
title = {Upadacitinib-Induced Remission in Multicentric Reticulohistiocytosis: Expanding the Therapeutic Role of JAK Inhibition},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {6},
pages = {2898},
doi = {10.3390/ijms27062898}
}
EUVIMED